FDA grants priority review to tabelecleucel for relapsed/refractory EBV+ PTLD, a critical step towards the first approved therapy for this severe posttransplant malignancy. PDUFA date Jan 10, 2026. #EBVPTLD #CellTherapy #FDA #Oncology www.targetedonc.com/view/fda-gra...
FDA Grants Priority Review to Tab-cel for EBV+ PTLD After Prior Therapies
Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.
www.targetedonc.com
July 25, 2025 at 5:43 PM
FDA grants priority review to tabelecleucel for relapsed/refractory EBV+ PTLD, a critical step towards the first approved therapy for this severe posttransplant malignancy. PDUFA date Jan 10, 2026. #EBVPTLD #CellTherapy #FDA #Oncology www.targetedonc.com/view/fda-gra...